NCT03101228

Medical and Physiological Benefits of Reduced Sitting

Completed NA Last updated 8 April 2020

What this trial tests

NA trial testing Reduced sitting in Metabolic Syndrome in 64 participants. Completed in 4 March 2020.

Timeline

25 April 2017

Primary endpoint
14 February 2020

4 March 2020

Quick facts

Lead sponsor	Turku University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	64
Start date	25 April 2017
Primary completion	14 February 2020
Estimated completion	4 March 2020
Sites	1 location across Finland

Drugs / interventions tested

• Reduced sitting

Conditions studied

• Metabolic Syndrome — all drugs for Metabolic Syndrome →
• Physical Activity — all drugs for Physical Activity →
• Insulin Resistance — all drugs for Insulin Resistance →
• Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Turku University Hospital

Who can join

Adults 40 to 65, any sex, with Metabolic Syndrome or Physical Activity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The most important objective of this randomized controlled trial in subjects with increased cardiovascular and metabolic risk factors is to investigate whether only reduced daily sitting improves human cardiovascular and metabolic health during a six-month intervention. It is hypothesized and expected that only reduced sitting, without formal physical activity or exercise training, affects favorably cardiovascular and metabolic health.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Both sedentary time and physical activity are associated with cardiometabolic health in overweight adults in a 1 month accelerometer measurement.
   Sjöros T, Vähä-Ypyä H, Laine S, Garthwaite T, et al · · 2020 · cited 36× · PMID 33239818 · DOI 10.1038/s41598-020-77637-3
2. Reducing Sedentary Time and Whole-Body Insulin Sensitivity in Metabolic Syndrome: A 6-Month Randomized Controlled Trial.
   Sjöros T, Laine S, Garthwaite T, Vähä-Ypyä H, et al · · 2023 · cited 25× · PMID 36251378 · DOI 10.1249/mss.0000000000003054
3. Body Adiposity, But Not Elements of Objectively Measured Sedentary Behavior or Physical Activity, Is Associated With Circulating Liver Enzymes in Adults With Overweight and Obesity.
   Laine S, Sjöros T, Vähä-Ypyä H, Garthwaite T, et al · · 2021 · cited 10× · PMID 33959099 · DOI 10.3389/fendo.2021.655756
4. Cross-Sectional Associations of Body Adiposity, Sedentary Behavior, and Physical Activity with Hemoglobin and White Blood Cell Count.
   Koivula T, Lempiäinen S, Laine S, Sjöros T, et al · · 2022 · cited 9× · PMID 36361221 · DOI 10.3390/ijerph192114347
5. Relationship between liver fat content and lifestyle factors in adults with metabolic syndrome.
   Laine S, Sjöros T, Garthwaite T, Saarenhovi M, et al · · 2022 · cited 8× · PMID 36261605 · DOI 10.1038/s41598-022-22361-3
6. Sedentary time associates detrimentally and physical activity beneficially with metabolic flexibility in adults with metabolic syndrome.
   Garthwaite T, Sjöros T, Laine S, Koivumäki M, et al · · 2024 · cited 7× · PMID 38416072 · DOI 10.1152/ajpendo.00338.2023
7. Influence of the Duration and Timing of Data Collection on Accelerometer-Measured Physical Activity, Sedentary Time and Associated Insulin Resistance.
   Sjöros T, Vähä-Ypyä H, Laine S, Garthwaite T, et al · · 2021 · cited 6× · PMID 34066552 · DOI 10.3390/ijerph18094950
8. Daily standing time, dietary fiber, and intake of unsaturated fatty acids are beneficially associated with hepatic insulin sensitivity in adults with metabolic syndrome.
   Laine S, Sjöros T, Garthwaite T, Honka MJ, et al · · 2024 · cited 5× · PMID 38989003 · DOI 10.3389/fendo.2024.1272886